Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors

Trial Profile

A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FPT 155 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Five Prime Therapeutics
  • Most Recent Events

    • 09 Nov 2019 According to a Five Prime Therapeutics media release, dose escalation with FPT155 is ongoing with the study currently enrolling patients at the 70 mg dose level.
    • 09 Nov 2019 Initial safety results from the Phase 1a dose escalation portion of this trial (n=15) presented at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, as reported in a Five Prime Media Release
    • 09 Nov 2019 Initial safety results from the Phase 1a dose escalation portion of the trial (n=15) published in the Five Prime Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top